Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-κB-dependent pathway

Journal of Immunology

Volumn 181, Issue 12, 2008, Pages 8441-8449

  Chen, Pei Hsuan ^a   Yang, Chia Ron ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; DECOY RECEPTOR 3; FAS LIGAND; HERBIMYCIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRROLIDINE DITHIOCARBAMATE; SMALL INTERFERING RNA; SOMATOMEDIN C; WORTMANNIN; CHUK PROTEIN, HUMAN; FASLG PROTEIN, HUMAN; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ESCAPE; ADENOCARCINOMA; BIOSYNTHESIS; CARCINOMA; CELL STRAIN HT29; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; IMMUNOLOGY; LEUKEMIA CELL LINE; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; FAS LIGAND PROTEIN; HT29 CELLS; HUMANS; I-KAPPA B KINASE; JURKAT CELLS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 58849100438     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.12.8441     Document Type: Article

References (47)

1. Pitti, R. M., S. A. Marsters, D. A. Lawrence, M. Roy, F. C. Kischkel, P. Dowd, A. Huang, C. J. Donahue, S. W. Sherwood, D. T. Baldwin, et al. 1998. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703.
2. Yu, K. Y., B. Kwon, J. Ni, Y. Zhai, R. Ebner, and B. S. Kwon. 1999. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 274: 13733-13736. (Pubitemid 129518665)
3. Migone, T. S., J. Zhang, X. Luo, L. Zhuang, C. Chen, B. Hu, J. S. Hong, J. W. Perry, S. F. Chen, J. X. Zhou, et al. 2002. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492.
4. Tsuji, S., R. Hosotani, S. Yonehara, T. Masui, S. S. Tulachan, S. Nakajima, H. Kobayashi, M. Koizumi, E. Toyoda, D. Ito, et al. 2003. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int. J. Cancer 106: 17-25.
5. Chang, Y. C., Y. H. Chan, D. G. Jackson, and S. L. Hsieh. 2006. The glyco-saminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion. J. Immunol. 176: 173-180.
6. You, R. I., Y. C. Chang, P. M. Chen, W. S. Wang, T. L. Hsu, C. Y. Yang, C. T. Lee, and S. L. Hsieh. 2008. Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 111: 1480-1488.
7. Hsu, T. L., Y. C. Chang, S. J. Chen, Y. J. Liu, A. W. Chiu, C. C. Chio, L. Chen, and S. L. Hsieh. 2002. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J. Immunol. 168: 4846-4853.
8. Chang, Y. C., T. L. Hsu, H. H. Lin, C. C. Chio, A. W. Chiu, N. J. Chen, C. H. Lin, and S. L. Hsieh. 2004. Modulation of macrophage differentiation and activation by decoy receptor 3. J. Leukocyte Biol. 75: 486-494. (Pubitemid 38316380)
9. Yang, C. R., J. H. Wang, S. L. Hsieh, S. M. Wang, T. L. Hsu, and W. W. Lin. 2004. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/ macrophage lineage precursor cells. Cell Death Differ. 11(Suppl. 1): S97-S107.
10. Ka, S. M., H. K. Sytwu, D. M. Chang, S. L. Hsieh, P. Y. Tsai, and A. Chen. 2007. Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice. J. Am. Soc. Nephrol. 18: 2473-2485.
11. Shi, G., Y. Wu, J. Zhang, and J. Wu. 2003. Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J. Immunol. 171: 3407-3414.
12. Lee, C. S., C. Y. Hu, H. F. Tsai, C. S. Wu, S. L. Hsieh, L. C. Liu, and P. N. Hsu. 2008. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin. Exp. Immunol. 151: 383-390.
13. Tang, C. H., T. L. Hsu, W. W. Lin, M. Z. Lai, R. S. Yang, S. L. Hsieh, and W. M. Fu. 2007. Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J. Biol. Chem. 282: 2346-2354.
14. Yang, C. R., S. L. Hsieh, F. M. Ho, and W. W. Lin. 2005. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-κB-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J. Immunol. 174: 1647-1656.
15. Ohshima, K., S. Haraoka, M. Sugihara, J. Suzumiya, C. Kawasaki, M. Kanda, and M. Kikuchi. 2000. Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett. 160: 89-97.
16. Takahama, Y., Y. Yamada, K. Emoto, H. Fujimoto, T. Takayama, M. Ueno, H. Uchida, S. Hirao, T. Mizuno, and Y. Nakajima. 2002. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5: 61-68. (Pubitemid 34832239)
17. Wu, Y., B. Han, H. Sheng, M. Lin, P. A. Moore, J. Zhang, and J. Wu. 2003. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int. J. Cancer 105: 724-732.
18. Li, H., L. Zhang, H. Lou, I. Ding, S. Kim, L. Wang, J. Huang, P. A. Di Sant'Agnese, and J. Y. Lei. 2005. Overexpression of decoy receptor 3 in pre-cancerous lesions and adenocarcinoma of the esophagus. Am. J. Clin. Pathol. 124: 282-287.
19. Roth, W., S. Isenmann, M. Nakamura, M. Platten, W. Wick, P. Kleihues, M. Bahr, H. Ohgaki, A. Ashkenazi, and M. Weller. 2001. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 61: 2759-2765.
20. Chang, Y. C., T. C. Chen, C. T. Lee, C. Y. Yang, H. W. Wang, C. C. Wang, and S. L. Hsieh. 2008. Epigenetic control of MHC-II expression in tumor-associated macrophages by decoy receptor 3. Blood 111: 5054-5063.
21. Yang, C. R., S. L. Hsieh, C. M. Teng, F. M. Ho, W. L. Su, and W. W. Lin. 2004. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res. 64: 1122-1129.
22. O'Reilly, E. M., and G. K. Abou-Alfa. 2007. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin. Oncol. 34: 347-353.
23. Russo, S., J. Butler, R. Ove, and A. W. Blackstock. 2007. Locally advanced pancreatic cancer: a review. Semin. Oncol. 34: 327-334. (Pubitemid 47176622)
24. Walker, P. R., P. Saas, and P. Y. Dietrich. 1997. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol. 158: 4521-4524.
25. Kim, S., A. Fotiadu, and K. Vassiliki. 2005. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin. Immunol. 115: 286-294. (Pubitemid 40712324)
26. Ciardiello, F., and G. Tortora. 2008. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358: 1160-1174.
27. Hartog, H., J. Wesseling, H. M. Boezen, and W. T. van der Graaf. 2007. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur. J. Cancer 43: 1895-1904. (Pubitemid 47284866)
28. Igney, F. H., and P. H. Krammer. 2005. Tumor counterattack: fact or fiction? Cancer Immunol. Immunother. 54: 1127-1136.
29. Xerri, L., E. Devilard, J. Hassoun, P. Haddad, and F. Birg. 1997. Malignant and reactive cells from human lymphomas frequently express Fas ligand but display a different sensitivity to Fas-mediated apoptosis. Leukemia 11: 1868-1877. (Pubitemid 27485132)
30. Vivanco, I., and C. L. Sawyers. 2002. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat. Rev. Cancer 2: 489-501. (Pubitemid 37328931)
31. Tokunaga, E., E. Oki, A. Egashira, N. Sadanaga, M. Morita, Y. Kakeji, and Y. Maehara. 2008. Deregulation of the Akt pathway in human cancer. Curr. Cancer Drug Targets 8: 27-36. (Pubitemid 351237907)
32. Fresno Vara, J. A., E. Casado, J. de Castro, P. Cejas, C. Belda-Iniesta, and M. Gonzalez-Baron. 2004. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30: 193-204.
33. Sell, C., G. Dumenil, C. Deveaud, M. Miura, D. Coppola, T. DeAngelis, R. Rubin, A. Efstratiadis, and R. Baserga. 1994. Effect of a null mutation of the insulin-like growth factor 1 receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 14: 3604-3612. (Pubitemid 24160768)
34. Bondar, V. M., B. Sweeney-Gotsch, M. Andreeff, G. B. Mills, and D. J. McConkey. 2002. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induced apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 1: 989-997.
35. Arlt, A., A. Gehrz, S. Muerkoster, J. Norndamm, M. L. Kruse, U. R. Folsch, and H. Schafer. 2003. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22: 3243-3251.
36. Datta, S. R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M. E. Greenberg. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
37. Cardone, M. H., N. Roy, H. R. Stennicke, G. S. Salvesen, T. F. Franke, E. Stanbridge, S. Frisch, and J. C. Reed. 1998. Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321.
38. Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis, and M. E. Greenberg. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
39. Mayo, L. D., and D. B. Donner. 2001. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 98: 11598-11603.
40. Romashdova, J. A., and S. S. Makarov. 1999. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401: 86-90. (Pubitemid 29418448)
41. Holcomb, B., M. Yip-Schneider, and C. M. Schmidt. 2008. The role of nuclear factor κB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 36: 225-235.
42. Wang, C. Y., M. W. Mayo, R. G. Korneluk, D. V. Goeddel, and A. S. Baldwin, Jr. 1998. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 28: 1680-1683.
43. Kajino, S., M. Suganuma, F. Teranishi, N. Takahashi, T. Tetsuka, H. Ohara, M. Itoh, and T. Okamoto. 2000. Evidence that de novo protein synthesis is dispensable for anti-apoptotic effects of NF-κB. Oncogene 19: 2233-2239.
44. Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100: 57-70.
45. Von Bernstorff, W., R. A. Spanjaard, A. K. Chan, D. C. Lockhart, N. Sadanaga, I. Wood, M. Peiper, P. S. Goedegebuure, and T. J. Eberlein. 1999. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/ CD95) receptors and aberrant expression of functional Fas ligand. Surgery 125: 73-84.
46. Li, W., C. Zhang, C. Chen, and G. Zhuang. 2007. Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. Cell Mol. Immunol. 4: 455-460.
47. Shen, H. W., S. L. Gao, Y. L. Wu, and S. Y. Peng. 2005. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J. Gastroenterol. 11: 5926-5930.